Innovent bets $250M+ on Union's PDE4 inhibitor ahead of a PhII readout
A year after plucking orismilast from Leo Pharmaceuticals’ pipeline — and without publishing any mid-stage data — Union Therapeutics is already making a pretty penny on the oral PDE4 inhibitor.
Innovent Biologics is shelling out $20 million upfront for development and commercialization rights to Union’s “Phase III-ready” oral formulation of orismilast in China, the companies said early Tuesday morning. Hoping to one-up Amgen’s blockbuster PDE4 inhibitor Otezla in terms of potency, Union’s been pushing the candidate through Phase II trials in skin conditions like psoriasis, atopic dermatitis and hidradenitis suppurativa.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.